Phase I clinical trial of HLA-A*2402 restricted epitope peptide cocktail therapy with S-1 for patients with unresectable advanced metastatic pancreatic cancer.
Phase 1
Completed
- Conditions
- pancreatic cancer
- Registration Number
- JPRN-UMIN000009881
- Lead Sponsor
- Sapporo Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 9
Inclusion Criteria
Not provided
Exclusion Criteria
1)Pregnancy or lactation 2)Patients with the intention of pregnancy. 3)Patients have uncontrollable severe infectional diseases. 4)severe diarrhea. 5)Patients who are treated with steroid or immunotherapy during clinical trial. 6)Patients have uncontrollable multiple cancer. 7)Patients who have non-recovered injury. 8)Patients who have ileus and interstitial lung disiease. 9)Patients whom doctors define as inappropriate.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does HLA-A*2402 restricted epitope peptide therapy synergize with S-1 in pancreatic cancer immunotherapy?
What is the comparative efficacy of HLA-A*2402 peptide cocktail plus S-1 versus standard chemotherapy in metastatic pancreatic cancer?
Which biomarkers correlate with response to HLA-A*2402 epitope peptides in Sapporo Medical University's pancreatic cancer trial?
What are the safety profiles of HLA-A*2402 targeted peptide therapy combined with S-1 in advanced pancreatic cancer patients?
Are there alternative HLA-restricted peptide combinations or competitor drugs for HLA-A*2402 positive pancreatic cancer treatment?